IFNG and melanoma: Furthermore, one recent report showed that PD‐1 inhibitor treatment of NSCLC patients and melanoma patients leads to higher IFNγ protein expression, accompanying with significantly longer progression‐free survival,15 indicating that IFNγ could be a biomarker for prediction of response to immune checkpoint blockade.